Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
RedactPHI
HIPAA-Compliant PHI Redaction
DetectICD10CM
ICD-10-CM Code Detection
Log in Register free account
1 code page views remaining. Guest accounts are limited to 1 page view. Register free account to get 5 more views.
Log in Register free account
Code deleted. See 91318, 91319, 91320, 91321, 91322.

Official Description

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 91306 refers to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, specifically designed to combat coronavirus disease (COVID-19). This vaccine utilizes a novel approach by employing messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), which is a cutting-edge technology in vaccine development. The mRNA contained in this vaccine encodes the spike protein of the SARS-CoV-2 virus, which is critical for the virus's ability to infect human cells. Upon administration, the mRNA instructs the body's cells to produce copies of the spike protein, which the immune system identifies as foreign. This triggers an immune response, leading to the production of antibodies that can recognize and neutralize the virus if the individual is exposed in the future. The vaccine is preservative-free and is administered in a dosage of 50 mcg per 0.25 mL via intramuscular injection. It is important to note that this code specifically reports the supply of Moderna's lower-dose vaccine product, which is intended for use as a booster for individuals aged 18 and older who have already received the initial Moderna vaccine. The administration of the vaccine itself is reported separately using the appropriate administration code, ensuring accurate billing and documentation for healthcare providers.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 91306 is indicated for the administration of the SARS-CoV-2 vaccine to provide immunity against COVID-19. The following conditions and circumstances warrant the use of this vaccine:

  • COVID-19 Prevention The vaccine is specifically designed to protect against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, a potentially severe and life-threatening disease.
  • Booster Dose for Adults This vaccine is indicated as a booster dose for adults aged 18 and older who have previously received the initial Moderna vaccine, enhancing their immune response against the virus.

2. Procedure

The administration of the CPT® Code 91306 vaccine involves several key procedural steps, which are outlined as follows:

  • Step 1: Preparation of the Vaccine The vaccine is drawn from a primary dose vial, ensuring that the correct dosage of 50 mcg per 0.25 mL is prepared for administration. It is crucial to follow aseptic techniques during this process to maintain sterility and prevent contamination.
  • Step 2: Patient Identification and Consent Prior to administration, healthcare providers must verify the patient's identity and confirm that they are eligible for the booster dose. Informed consent should be obtained, explaining the benefits and potential side effects of the vaccine.
  • Step 3: Administration of the Vaccine The vaccine is administered via intramuscular injection, typically in the deltoid muscle of the upper arm. Proper injection techniques should be employed to ensure effective delivery of the vaccine into the muscle tissue.
  • Step 4: Post-Administration Monitoring After the injection, patients should be monitored for a short period to observe for any immediate adverse reactions. This is a standard practice to ensure patient safety following vaccination.

3. Post-Procedure

Following the administration of the CPT® Code 91306 vaccine, patients are advised to remain in the healthcare setting for a brief observation period to monitor for any immediate side effects or allergic reactions. Common post-vaccination care includes advising patients to rest and hydrate adequately. They should also be informed about potential side effects, which may include soreness at the injection site, fatigue, headache, or mild fever. Patients should be encouraged to report any unusual or severe reactions to their healthcare provider. Additionally, it is important to remind patients of the need for follow-up vaccinations if applicable, and to continue practicing preventive measures against COVID-19, such as wearing masks and social distancing, until they are fully vaccinated and protected.

Short Descr SARSCOV2 VAC 50MCG/0.25ML IM
Medium Descr SARSCOV2 VACCINE 50 MCG/0.25 ML IM USE
Long Descr Severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use
Status Code Not Valid for Medicare Purposes
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Non-Covered Service, not paid under OPPS
Berenson-Eggers TOS (BETOS) none
MUE Not applicable/unspecified.
SL State supplied vaccine
Date
Action
Notes
2025-01-01 Deleted First appearance of code deletion in codebook.
2024-01-01 Note First appearance of 2022 guideline updates to codebook.
2023-11-01 Deleted Code deleted. See 91318, 91319, 91320, 91321, 91322.
2023-04-18 Note Changes made to dosing information
2023-04-18 Note These codes (included in the guidelines) are no longer authorized for use in the United States: 0011A, 0012A, 0013A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A.
2023-04-18 Note AMA guidelines changed to include 0141A, & 0142A. Published to website 2023-05-01. Received FDA approval effective retroactively to 2023-04-18.
2023-04-18 Note No longer authorized for use in the United States.
2023-01-01 Added First appearance in codebook.
2023-01-01 Note First appearance of guideline change(s) in codebook.
2022-12-08 Note AMA Guideline changed. 0164A received FDA approval.
2022-11-16 Note AMA guideline changed to include 0164A effective upon receiving Emergency Use Authorization or approval from the FDA
2022-10-12 Note AMA Guideline changed. 0134A(12–17 yrs) and 0144A received FDA approval.
2022-08-31 Note Changes made to vaccine name, product & dosing information, & patient age to (18+).
2022-08-31 Note AMA Guideline changed. 0134A(18 yrs and older) received FDA approval effective immediately.
2022-08-31 Note AMA guideline changed to include 0134A, 0144A effective upon receiving emergency Use Authorization or approval from the FDA.
2022-06-17 Note AMA guideline changed to include 0091A, 0092A, 0093A, 0113A added to website 2022-07-06. FDA approval received. Effective retroactively to 2022-06-17.
2022-06-17 Note AMA Guideline changed. 0111A, 0112A received FDA approval
2022-05-19 Note New AMA guideline added. Codes 0111A & 0112A Published to website. Effective upon receiving Emergency Use Authorization or approval from the FDA
2022-05-19 Note New AMA guideline added. Codes 0011A, 0012A, 0013A added to website & received FDA approval prior to the addition of this new guideline.
2022-03-29 Note AMA Guideline changed. 0094A received FDA approval.
2022-03-07 Note AMA guideline changed to include 0094A effective upon receiving Emergency Use Authorization or approval from the FDA.
2021-10-20 Added FDA approval received.
2021-10-20 Note AMA Guideline changed. 0064A received FDA approval.
2021-09-03 Note AMA guideline includes 0064A effective upon receiving Emergency Use Authorization or approval from the FDA.
2021-09-03 Added Published on AMA website. Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"